Production (Stage)
E
Autolus Therapeutics plc AUTL
$1.54 $0.010.65% NASDAQ
Recommendation
Prev Close
$1.54
Volume
1,154,401
Avg Vol (90D)
1,707,010
Market Cap
$409.86M
Dividend & Yield
--
52-Week Range
$1.11 - $5.00
P/E (TTM)
--
EPS (TTM)
-$0.8948
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Autolus Therapeutics Gets Favorable Recommendation For Approval Of Cancer Therapy In EU: Retail Sentiment Brightens
5/23/2025 - Stocktwits News Feed
Autolus Therapeutics (AUTL) Secures EMA Panel Endorsement for Leukemia Therapy
5/23/2025 - GuruFocus
Autolus Therapeutics gets EU endorsement for leukemia treatment
5/23/2025 - SeekingAlpha.com: All News
Autolus Therapeutics gets EU endorsement for leukemia treatment
5/23/2025 - Seeking Alpha - Healthcare
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult ...
5/23/2025 - GuruFocus
Autolus Therapeutics (AUTL) Secures Key EU Panel Recommendation for Obe-cel AUTL Stock News
5/23/2025 - GuruFocus
Autolus Therapeutics announces positive CHMP opinion for obe-cel
5/23/2025 - The Fly
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
5/23/2025 - Globe Newswire
Point72 Asset Management L.P. Makes New Investment in Autolus Therapeutics plc (NASDAQ:AUTL)
5/23/2025 - Ticker Report
Autolus Therapeutics plc (AUTL): Analysts See 697% Upside Potential
5/20/2025 - Insider Monkey
TFG Asset Management GP Ltd Buys 250,000 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)
5/20/2025 - MarketBeat
Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association ...
5/14/2025 - GuruFocus
Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association ...
5/14/2025 - GuruFocus
Autolus Therapeutics (AUTL) Unveils Promising Findings at EHA Congress AUTL Stock News
5/14/2025 - GuruFocus
Autolus Therapeutics presents clinical data updates at EHA Congress
5/14/2025 - The Fly
Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress
5/14/2025 - Globe Newswire
Syncona Portfolio Ltd Expands Stake in Autolus Therapeutics PLC
5/14/2025 - GuruFocus
Autolus Therapeutics (NASDAQ:AUTL) Issues Quarterly Earnings Results
5/12/2025 - MarketBeat
Autolus Therapeutics plc (NASDAQ:AUTL) Receives Consensus Rating of "Buy" from Analysts
5/12/2025 - MarketBeat
Autolus Therapeutics plc (AUTL) Q1 2025 Earnings Call Transcript
5/11/2025 - Seeking Alpha: Transcripts
Autolus Therapeutics plc 2025 Q1 - Results - Earnings Call Presentation
5/9/2025 - SeekingAlpha
Bayesian Capital Management LP Increases Holdings in Autolus Therapeutics plc (NASDAQ:AUTL)
5/9/2025 - Ticker Report
Autolus Therapeutics PLC (AUTL) Q1 2025 Earnings Call Highlights: Strong US Launch and ...
5/9/2025 - GuruFocus
Q1 2025 Autolus Therapeutics PLC Earnings Call Transcript
5/9/2025 - GuruFocus
Autolus Therapeutics files to sell 54.58M American depositary shares for holders
5/8/2025 - TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
$9.01M
EBITDA (TTM)
-$259.08M
EBIT (TTM)
-$267.27M
Net Income (TTM)
-$238.13M
Balance Sheet
Total Assets (Q)
$746.34M
Total Debt (Q)
$311.15M
Total Liabilities (Q)
$375.23M
Book Value Per Share (Q)
$1.39
Cash Flow
Cash from Operations (TTM)
-$241.32M
Cash from Investing (TTM)
-$453.57M
Cash from Financing (TTM)
$28.11M
Net Change in Cash (TTM)
-$662.29M
Filings
Filing Date
Thursday, May 8, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 4 and 8 (est)
Price History
Loading...
Beta
1.20
7-Day Total Return
19.38%
30-Day Total Return
13.24%
60-Day Total Return
-10.98%
90-Day Total Return
-33.91%
Year to Date Total Return
-41.44%
1-Year Total Return
-60.71%
2-Year Total Return
-50.48%
3-Year Total Return
-40.77%
5-Year Total Return
-87.18%
52-week Low
Apr 11, 2025 - $1.11
52-week High
Oct 18, 2024 - $5.00
Valuation
Market Cap
$409.86M - Small Cap
Enterprise Value
$204.43M
Price/Sales (TTM)
45.56
Price/Book (Q)
1.10
Dividends and Shares
Shares Outstanding
266.13M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.autolus.com
Phone Number
44 20 3829 6230
Address
The Mediaworks
191 Wood Lane - White City
London, W12 7FP
Country
United Kingdom
Year Founded
2014
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in United Kingdom and internationally. The... more
NASDAQ 05/23/2025 4:00PM Eastern Quotes delayed